Radotinib (IY5511HCL). a novel and selective BCR-ABL1 tyrosine kinase inhibitor. has shown pre-clinical and phase I activity and safety in chronic myeloid leukemia. This phase II study investigated the efficacy and safety of radotinib in Philadelphia chromosome-positive chronic phase-chronic myeloid leukemia patients with resistance and/or intolerance to BCR-ABL1 tyrosine kinase inhib... https://www.roneverhart.com/Nike-Dunk-Low-Polar-Blue/